Real World Effectiveness of fixed combination of glargine 100 U/ml and lixisenatide therapy in outpatients with Type 2 Diabetes: A Retrospective Cohort Study SOLO

Antsiferov, M.B. Antsiferov; Demidov, Nikolay A.; Balberova, M. A.; Safronova, T. I.; Mishra, O. A.; Magomedova, S. G.

doi:10.14341/dm12809

Search citation statements

Order By: Relevance

Paper Sections

Select...

доказательства полученные в реальной клинической практике1

Citation Types

Supporting

Mentioning

Contrasting

Unclassified

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…В исследование были включены данные электронных медицинских карт 383 взрослых пациентов с СД2 на терапии иГларЛикси. Согласно полученным результатам, терапия иГларЛикси приводила к снижению HbA1c в среднем на 1,74% через 12 месяцев, а также к уменьшению массы тела в среднем на 3,13 кг (p<0,001) без увеличения риска гипогликемий по сравнению с исходным уровнем [ 35 ].…”

Section: доказательства полученные в реальной клинической практикеunclassified

Fixed ratio combinations GLP-1RA and basal insulin: literature review

Kurkin,

Bakulin,

Morkovin

et al. 2024

Probl Endokrinol (Mosk)

View full text Add to dashboard Cite

The progressive nature of type 2 diabetes mellitus leads to the need for insulin therapy in a significant proportion of patients. Very often start of insulin therapy in type 2 diabetes mellitus (T2DM) is associated with weight gain and a significant increase of hypoglycemia’s risk. However, innovative options, such as fixed ratio combinations of glucagon-like peptide 1 receptor agonists (GLP-1RA) and basal insulin, minimize weight gain and hypoglycemia risks and allow a greater proportion of patients to achieve individual glycemic control goals without compromising safety parameters. This review includes a description of the randomized clinical trials, as well as the results of real clinical practice of the use of two currently existing fixed ration combinations of GLP-1RA and basal insulin — iDegLira and iGlarLixi.

show abstract

Section: доказательства полученные в реальной клинической практикеunclassified